Co-Diagnostics, a company with a patented platform for the development of molecular diagnostic tests, held a ribbon-cutting event for its new manufacturing facility yesterday in the City of South Salt Lake, UT. 

Co-Diagnostics’ New Co-Dx Pro instrument

The facility has been designed to manufacture the company’s Co-Dx Pro instrument and test cups for the new platform*, as well as its patented Co-Primers chemistry that underpins the company’s PCR diagnostic tests.

“This new facility represents a significant step towards establishing Co-Diagnostics as a key player both in the local community, and also on the international stage as we pursue our mission of closing the access gap to high-quality, equitable diagnostics that exists around the world,” says Co-Dx CEO Dwight Egan. “We are pleased with the work that our team has put into bringing this facility online and grateful for the support of Mayor Wood and other community leaders.”

Manufacturing Facilities Ribbon-Cutting Event

In attendance were South Salt Lake Mayor Cherie Wood and other leaders and dignitaries, including Kelvyn Cullimore, the president and CEO of BioUtah, an independent trade organization serving the Utah life sciences community and focused on growing Utah into a global life sciences leader.

“I am pleased Co-Diagnostics is establishing a manufacturing campus in the City of South Salt Lake. We are excited about their plans to add employees, offer our residents quality jobs, and drive economic development in the City On The Move,” Mayor Wood said at the ceremony.

Further reading: Co-Diagnostics Completes Submission to FDA for PCR COVID Test

Kelyvn Cullimore of BioUtah commented, “We believe that Co-Diagnostics’ success over the past several years, which has helped them to reach this noteworthy milestone, exemplifies the entrepreneurial mindset of the state of Utah as a whole, as well as the attitude, work ethic and vision that have contributed to the Utah life science industry being one of the 3 fastest growing in the country.”

*The Co-Dx PCR platform (including the PCR Home, PCR Pro, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.

Featured image: From left to right: David Nielsen, Mark Welcker, Genevieve Rawlins, Chandler Beutler, Cody Schlottmann, Kelvyn Cullimore, Mayor Cherie Wood, Dwight Egan, David Carlebach, Kirk Ririe, Jim Grover, Lance Soffe, Richard Abbott. Photo: Co-Diagnostics